DOCSLIB.ORG

FIRST of 2 PARTS Web Video at Currentpsychiatry.Com Dr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FIRST of 2 PARTS Web Video at Currentpsychiatry.Com Dr FIRST OF 2 PARTS Web video at CurrentPsychiatry.com Dr. Meyer: What to tell patients about diet and monoamine oxidase inhibitors A concise guide to monoamine oxidase inhibitors A better understanding of the risks can lead to increased use of these highly effective agents Jonathan M. Meyer, MD espite an abundance of evidenced-based literature supporting Psychopharmacology Consultant monoamine oxidase inhibitors (MAOIs) as an effective treat- California Department of State Hospitals Sacramento, California Dment for depression, use of these agents has decreased drasti- Assistant Clinical Professor of Psychiatry cally in the past 3 decades. A lack of industry support and the ease of University of California, San Diego use of other agents are contributing factors, but the biggest impedi- San Diego, California Deputy Editor, CURRENT PSYCHIATRY ments to routine use of MAOIs are unfamiliarity with their efficacy Disclosure advantages and concerns about adverse effects, particularly the risk Dr. Meyer is a consultant to Acadia Pharmaceuticals, of hypertensive crises and serotonin syndrome. Many misconceptions Neurocrine Biosciences, Inc., and Teva Pharmaceutical regarding these medications are based on outdated data and studies Industries; and is a speaker for Acadia Pharmaceuticals, Alkermes, Allergan, Merck, Neurocrine Biosciences, Inc., that are no longer reliable. Otsuka America, Inc., Sunovion Pharmaceuticals, and The goal of this 2-part review is to provide clinicians with updated Teva Pharmaceutical Industries. information regarding MAOIs. Part 1 provides a brief description of: • the pharmacology of nonselective irreversible MAOIs • the mechanism by which tyramine induces hypertension • sources of clinically significant tyramine exposure • what to tell patients about dietary restrictions and MAOIs. Part 2 of this guide will cover the risk of serotonin syndrome when MAOIs are combined with inhibitors of serotonin reuptake, how to initi- ate MAOI therapy, and augmenting MAOIs with other agents. The pharmacology of MAOIs First used clinically in the 1950s to treat tuberculosis, MAOIs have a long and interesting history (see the Box “A brief history of monoamine oxidase inhibitors” on CurrentPsychiatry.com). Table 11 (page 16) lists Current Psychiatry ALEX NABAUM Vol. 16, No. 12 15 Table 1 MAOIs available in the United States Drug (brand name, approval date) MAO-A/B Dose Comments, adverse effects Isocarboxazid 1:1 Start: 10 mg AEs: Sexual dysfunction, weight gain, orthostasis, (Marplan, 7/1/59) at bedtime hypertensive events, serotonin syndrome Monoamine Max: 60 mg/d oxidase inhibitors Phenelzine 1:1 Start: 15 mg AEs: Sexual dysfunction, weight gain, orthostasis, (Nardil, 6/9/61) at bedtime hypertensive events, serotonin syndrome Max: 90 mg/d Tranylcypromine 1:1 Start: 10 mg No known L-amphetamine metabolites, but can be (Parnate, 2/21/61) at bedtime stimulating at higher doses Max: 60 mg/d AEs: Sexual dysfunction, weight gain, orthostasis, hypertensive events, serotonin syndrome Selegiline 1:1 Start: No dietary restrictions at lowest dose (6 mg/24 h). Has (transdermal) 6 mg/24 h L-methamphetamine metabolites; can be stimulating Clinical Point (Emsam, 2/27/06) Max: at higher doses. Also, has potential for false-positive 12 mg/24 h drug screen Nonselective MAOIs AEs: Insomnia, site reaction, hypertensive events, offer a therapeutic serotonin syndrome opportunity for Rasagiline 1:14 (Only used for Lacks L-amphetamine metabolites. No risk (Azilect, 5/16/06) Parkinson’s of hypertensive crises. No cases of serotonin patients who do not disease) syndrome when combined with antidepressants in large review (n = 1,504),1 but the package respond to single insert warns about use with inhibitors of serotonin or dual-mechanism reuptake, including antidepressants, meperidine, tramadol, and methadone strategies AEs: Adjunctive use: orthostasis and falls, peripheral edema, dyskinesia, abnormal dreams, nausea. Risk of serotonin syndrome not seen in large samples, although the package insert includes warnings Selegiline (oral) 5 mg, (Only used for Short half-life requires multiple daily dosing. Lower (Eldepryl, 4/17/89) twice a Parkinson’s plasma levels for oral than transdermal results in day: 1:10 disease) limited MAO-A inhibition. Oral bioavailability 4% vs >20 mg/d: 75% for transdermal 1:1 AEs: Nausea, dizziness/orthostasis/falls, abdominal pain AE: adverse effect; MAO: monoamine oxidase MAOIs currently available in the United tonin norepinephrine reuptake inhibitors, States, including the MAO-B–specific mirtazapine, or bupropion, necessitating agent rasagiline, which is used for consideration of antidepressant combina- Parkinson’s disease. tions, augmentation options, and eventu- Manipulation of the monoamines sero- ally irreversible, nonselective MAOIs such tonin, norepinephrine, and dopamine is as phenelzine, tranylcypromine, or isocar- fundamental to managing major depres- boxazid.3,4 Nonselective MAOIs thus offer Discuss this article at sive disorder (MDD), yet only nonselective a therapeutic opportunity for patients who www.facebook.com/ MAOIs directly promote neurotransmission do not respond to single or dual-mechanism CurrentPsychiatry of all 3 by inhibiting MAO-A and MAO-B.2 strategies; moreover, nonselective MAOIs The Sequenced Treatment Alternatives to have compelling effectiveness data for Relieve Depression (STAR*D) study demon- other conditions, including panic disorder strated that <50% of MDD patients achieve and social phobia.5 Although MAOIs are remission in monotherapy trials of selec- among the most effective pharmacologic Current Psychiatry 16 December 2017 tive serotonin reuptake inhibitors, sero- agents for MDD,6 they are underutilized continued on page 18 continued from page 16 Table 2 Substrates for monoamine oxidase enzymes MAO-A MAO-B Substrates Serotonin Dopamine Norepinephrine Phenylethylamine Dopamine Monoamine Tyramine oxidase inhibitors Tissue localization Brain, gut, liver, placenta, skin Brain, platelets, lymphocytes MAO: monoamine oxidase Source: References 9,10 Figure 1 Comparative gut monoamine oxidase inhibition of transdermal and oral selegiline in an animal model Clinical Point Transdermal Oral 100 Cortex 100 Cortex CNS MAO-A 90 Duodenum 90 Duodenum inhibition is 80 Liver 80 Liver 70 70 n necessary for 60 60 antidepressant 50 50 40 40 effects % Inhibitio 30 30 20 20 10 10 Patch area 0 0 (cm2)/24 hr 0.4 0.71 1.0 1.5 2.0 2.5 3.75 5 10 0.10.3 13510152030545 0 100 mg kg1/24 hr 0.68 1.24 1.76 2.68 3.6 4.55 7.37 9.9 21.29 Daily dose (mg/kg) Source: Reference 12 because of an inadequate understanding of discerned that norepinephrine was only a risk mechanisms and resultant fear of cata- substrate for MAO-A, and that this form of strophic outcomes. Because of the difficulties MAO was sensitive to clorgyline inhibition. encountered in achieving clinical remission Thus, the forms of MAO were characterized for MDD, the nonselective MAOIs deserve by their preferred substrates (Table 29,10), a second look. and then later by their tissue distribution. Phenylethylamine is a naturally occurring Differentiation of MAO-A from MAO-B. It compound found in foods, such as choco- is essential to understand the mechanism of late, and has an in vitro pharmacology simi- action of MAOIs, specifically the impact of lar to amphetamine but with 1 important MAO-A inhibition. Although the enzyme difference: it has a short half-life of 5 to 10 MAO was known in the 1950s, it wasn’t until minutes after oral ingestion, and therefore 1968 that Johnston7 postulated the existence no appreciable CNS impact. of >1 form. In 1971, Goridis and Neff8 used Within the CNS, norepinephrine and clorgyline to examine the deamination rate dopamine neurons possess both MAO by MAO of tyramine and norepinephrine. forms, with the MAO-A content greater They found that tyramine appeared to be a than MAO-B. Serotonergic neurons only substrate of both MAO isoforms, but only contain MAO-B.11 Outside of the CNS, 1 of the MAO types was sensitive to the MAO-A predominates, with only plate- Current Psychiatry 18 December 2017 inhibitory effects of clorgyline. They also lets and lymphocytes possessing MAO-B Figure 2 Chemical classification of nonselective monoamine oxidase inhibitors CH3 O H N N H CH3 N IPRONIAZID O N NH2 H N NH N 2 H H CH3 N O Clinical Point Patients taking ISOCARBOXAZID PHENELZINE selegiline should (Hydrazine) (Hydrazine) TRANYLCYPROMINE disclose their use of (Nonhydrazine) this medication prior to undergoing drug testing procedures activity.11 The overall relative tissue pro- Differentiation of MAOIs by chemi- portions of MAO-A to MAO-B activity cal class. The earliest MAOI, iproniazid, are: brain, 25% MAO-A, 75% MAO-B; liver, was a hydrazine derivative and exhib- 50% MAO-A, 50% MAO-B; intestine, 80% ited hepatotoxicity,13 as did certain other MAO-A, 20% MAO-B; and peripheral adren- hydrazine MAOIs. This lead to a search for ergic neurons, 90% MAO-A, 10% MAO-B. safer hydrazine and nonhydrazine alter- Because of its specificity for serotonin natives. Isocarboxazid and phenelzine are and norepinephrine, CNS MAO-A inhibi- the 2 hydrazine MAOIs available in the tion is necessary for antidepressant effects. United States, while tranylcypromine and MAO-B inhibition by itself does not appear selegiline transdermal are nonhydrazines to raise CNS dopamine levels unless exog- (Figure 2). enous dopamine is supplied.11 All MAOIs What distinguishes the nonhydra- used in the United States to treat depres- zine medication selegiline is that its sion are irreversible, nonselective inhibitors of metabolism generates L-amphetamine MAO-A and MAO-B. metabolites (Figure 3,14 page 20). This Selegiline in oral form generates low property was thought to be shared by plasma levels and primarily inhibits MAO-B. other non hydrazines, but recent studies The transdermal form of selegiline achieves indicate than neither tranylcypromine15 significantly greater systemic exposure, and nor the MAO-B–selective rasagiline pos- at these higher plasma levels selegiline is a sess amphetamine metabolites.16 Unlike nonselective, irreversible MAOI effective for the dextro isomers, L-amphetamine struc- MDD (Figure 1,12 page 18).
Load more

Recommended publications
  • Studies on Mammalian Histidine Decarboxylase by N
    Brit. J. Pharmacol. (1956), 11, 119. STUDIES ON MAMMALIAN HISTIDINE DECARBOXYLASE BY N. G. WATON* From the Department ofPharmacology, University ofEdinburgh (RECEIVED SEPTEMBER 12, 1955) Histamine is present in most mammalian tissues, occurrence of an enzyme capable of decarboxylating but its mode of formation is still not clear. Accord- histidine in all mammals, as the experiments were ing to Blaschko (1945) there are two main theories: confined to a limited range of mammalian species. (1) Histamine is a vitamin, formed outside the The properties and the distribution in laboratory body by bacterial decarboxylation of dietary animals of mammalian histidine decarboxylase, histidine in the alimentary tract. (2) Histamine is a together with the distribution of histaminase and metabolite, formed from circulating histidine by histamine, have been reinvestigated in the hope of the histidine decarboxylase present in some tissues clarifying our knowledge of the role of histamine in of the body. the organism. That bacteria form histamine by decarboxylation METHODS of histidine is well known (Ackermann, 1910, 1911; Formation of Histamine from Histidine by Mammalian Berthelot and Bertrand, 1912; Mellanby and Twort, Tissues 1912; Kendall and Gebauer, 1930; Matsuda, 1933; Rabbit kidneys, which are a rich source of histidine Gale, 1940; Epps, 1945). Gale (1953) showed that decarboxylase, were placed in 0.9% w/v NaCl, freed the bacterial enzyme had several important differen- from all extraneous tissue, cut small and minced in a ces from the other amino acid decarboxylases which Latapie mincing machine. Where a tissue extract was had been studied. required, the minced kidney was ground for 10 min.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
    [Show full text]
  • Parkinson Disease-Associated Cognitive Impairment
    PRIMER Parkinson disease-associated cognitive impairment Dag Aarsland 1,2 ✉ , Lucia Batzu 3, Glenda M. Halliday 4, Gert J. Geurtsen 5, Clive Ballard 6, K. Ray Chaudhuri 3 and Daniel Weintraub7,8 Abstract | Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting >1% of the population ≥65 years of age and with a prevalence set to double by 2030. In addition to the defining motor symptoms of PD, multiple non-motor symptoms occur; among them, cognitive impairment is common and can potentially occur at any disease stage. Cognitive decline is usually slow and insidious, but rapid in some cases. Recently, the focus has been on the early cognitive changes, where executive and visuospatial impairments are typical and can be accompanied by memory impairment, increasing the risk for early progression to dementia. Other risk factors for early progression to dementia include visual hallucinations, older age and biomarker changes such as cortical atrophy, as well as Alzheimer-type changes on functional imaging and in cerebrospinal fluid, and slowing and frequency variation on EEG. However, the mechanisms underlying cognitive decline in PD remain largely unclear. Cortical involvement of Lewy body and Alzheimer-type pathologies are key features, but multiple mechanisms are likely involved. Cholinesterase inhibition is the only high-level evidence-based treatment available, but other pharmacological and non-pharmacological strategies are being tested. Challenges include the identification of disease-modifying therapies as well as finding biomarkers to better predict cognitive decline and identify patients at high risk for early and rapid cognitive impairment. Parkinson disease (PD) is the most common movement The full spectrum of cognitive impairment occurs in disorder and the second most common neurodegenera­ individuals with PD, from subjective cognitive decline tive disorder after Alzheimer disease (AD).
    [Show full text]
  • The Effects of Phenelzine and Other Monoamine Oxidase Inhibitor
    British Journal of Phammcology (1995) 114. 837-845 B 1995 Stockton Press All rights reserved 0007-1188/95 $9.00 The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver 12 imidazoline-preferring receptors Regina Alemany, Gabriel Olmos & 'Jesu's A. Garcia-Sevilla Laboratory of Neuropharmacology, Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, E-07071 Palma de Mallorca, Spain 1 The binding of [3H]-idazoxan in the presence of 106 M (-)-adrenaline was used to quantitate 12 imidazoline-preferring receptors in the rat brain and liver after chronic treatment with various irre- versible and reversible monoamine oxidase (MAO) inhibitors. 2 Chronic treatment (7-14 days) with the irreversible MAO inhibitors, phenelzine (1-20 mg kg-', i.p.), isocarboxazid (10 mg kg-', i.p.), clorgyline (3 mg kg-', i.p.) and tranylcypromine (10mg kg-', i.p.) markedly decreased (21-71%) the density of 12 imidazoline-preferring receptors in the rat brain and liver. In contrast, chronic treatment (7 days) with the reversible MAO-A inhibitors, moclobemide (1 and 10 mg kg-', i.p.) or chlordimeform (10 mg kg-', i.p.) or with the reversible MAO-B inhibitor Ro 16-6491 (1 and 10 mg kg-', i.p.) did not alter the density of 12 imidazoline-preferring receptors in the rat brain and liver; except for the higher dose of Ro 16-6491 which only decreased the density of these putative receptors in the liver (38%). 3 In vitro, phenelzine, clorgyline, 3-phenylpropargylamine, tranylcypromine and chlordimeform dis- placed the binding of [3H]-idazoxan to brain and liver I2 imidazoline-preferring receptors from two distinct binding sites.
    [Show full text]
  • Azilect, INN-Rasagiline
    SCIENTIFIC DISCUSSION 1. Introduction AZILECT is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Rasagiline is administered orally, at a dose of 1 mg once daily with or without levodopa. Parkinson’s disease is a common neurodegenerative disorder typified by loss of dopaminergic neurones from the basal ganglia, and by a characteristic clinical syndrome with cardinal physical signs of resting tremor, bradikinesia and rigidity. The main treatment aims at alleviating symptoms through a balance of anti-cholinergic and dopaminergic drugs. Parkinson’s disease (PD) treatment is complex due to the progressive nature of the disease, and the array of motor and non-motor features combined with early and late side effects associated with therapeutic interventions. Rasagiline is a chemical inhibitor of the enzyme monoamine oxidase (MAO) type B which has a major role in the inactivation of biogenic and diet-derived amines in the central nervous system. MAO has two isozymes (types A and B) and type B is responsible for metabolising dopamine in the central nervous system; as dopamine deficiency is the main contributing factor to the clinical manifestations of Parkinson’s disease, inhibition of MAO-B should tend to restore dopamine levels towards normal values and this improve the condition. Rasagiline was developed for the symptomatic treatment of Parkinson’s disease both as monotherapy in early disease and as adjunct therapy to levodopa + aminoacids decarboxylase inhibitor (LD + ADI) in patients with motor fluctuations. 2. Quality Introduction Drug Substance • Composition AZILECT contains rasagiline mesylate as the active substance.
    [Show full text]
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics
    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
    [Show full text]
  • (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
    pharmaceuticals Review Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Andreia Machado Brito-da-Costa 1 , Diana Dias-da-Silva 1,2,* , Nelson G. M. Gomes 1,3 , Ricardo Jorge Dinis-Oliveira 1,2,4,* and Áurea Madureira-Carvalho 1,3 1 Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal; [email protected] (A.M.B.-d.-C.); ngomes@ff.up.pt (N.G.M.G.); [email protected] (Á.M.-C.) 2 UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 3 LAQV-REQUIMTE, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 4 Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal * Correspondence: [email protected] (D.D.-d.-S.); [email protected] (R.J.D.-O.); Tel.: +351-224-157-216 (R.J.D.-O.) Received: 21 September 2020; Accepted: 20 October 2020; Published: 23 October 2020 Abstract: Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids.
    [Show full text]
  • Nialamide; SOCIETIES and LECTURES CORRECTION
    414 BRITISH MEDICAL JOURNAL 15 MAY 1971 care, and administration of health services. A. Clements, P. A. Connell, Patricia A. Crawford, G. A. Cupper, M. R. Dean, L. L. Dom- "It is, in short, medicine applied to a group SOCIETIES AND LECTURES bey, D. P. De Bono, J. P. Delamere, Gil- than to an individual patient." The lean P. Duncan, D. B. Dunger, C. E. G. Farqu- rather Br Med J: first published as 10.1136/bmj.2.5758.414 on 15 May 1971. Downloaded from statement adds that it is hoped that the pro- For attending lectures marked * a fee is charged or harson, Pamela C. Fenney, Daphne C. Fielding, a ticket is required. Applications should be made I. R. Fletcher, M. S. Fletcher, Po-Kai Fok, G. J. visional Faculty will be in a position to re- Frost, R. M. Galbraith, Elizabeth A. S. Galvin, first to the institution concerned. D. J. Giraldi, Jenifer I. Glover, B. A. Greenway, ceive applications from those wishing to be- Mary Griffin, J. F. Hamlyn, M. H. Hampton, come founder members later in the year. Monday, 17 May G. P. Harris, P. B. Harvey, A. C. Hillyard, Gillian M. M. Hodge, N. Holmes, Sheilagh M. Further announcements will be made. ABERDEEN UNIVERSITY.-At Medical Buildings, Hope, C. C. Hugh, Joanna E. Ide, Alison Ironside, Foresterhill, 5.30 p.m., dentj centennial lecture Keatley E. James, W. J. Jarrett, Celia A. Jenkins, by Sir Robert Bradlaw: Pigmentation. J. R. Jenner, P. D. Jones, C. L. Kennedy, N. D. Monoamine-oxidase Inhibitors INSTITUTE OF DERMATOLOGY.-4.30 p.m., Mr.
    [Show full text]
  • 3 Drugs That May Cause Delirium Or Problem Behaviors CARD 03 19 12 JUSTIFIED.Pub
    Drugs that May Cause Delirium or Problem Behaviors Drugs that May Cause Delirium or Problem Behaviors This reference card lists common and especially problemac drugs that may Ancholinergics—all drugs on this side of the card. May impair cognion cause delirium or contribute to problem behaviors in people with demena. and cause psychosis. Drugs available over‐the‐counter marked with * This does not always mean the drugs should not be used, and not all such drugs are listed. If a paent develops delirium or has new problem Tricyclic Andepressants Bladder Anspasmodics behaviors, a careful review of all medicaons is recommended. Amitriptyline – Elavil Darifenacin – Enablex Be especially mindful of new medicaons. Clomipramine – Anafranil Flavoxate – Urispas Desipramine – Norpramin Anconvulsants Psychiatric Oxybutynin – Ditropan Doxepin – Sinequan Solifenacin – VESIcare All can cause delirium, e.g. All psychiatric medicaons should be Imipramine – Tofranil Tolterodine – Detrol Carbamazepine – Tegretol reviewed as possible causes, as Nortriptyline – Aventyl, Pamelor Gabapenn – Neuronn effects are unpredictable. Trospium – Sanctura Anhistamines / Allergy / Leveracetam – Keppra Notable offenders include: Insomnia / Sleep Valproic acid – Depakote Benzodiazepines e.g. Cough & Cold Medicines *Diphenhydramine – Sominex, ‐Alprazolam – Xanax *Azelasne – Astepro Pain Tylenol‐PM, others ‐Clonazepam – Klonopin *Brompheniramine – Bromax, All opiates can cause delirium if dose *Doxylamine – Unisom, Medi‐Sleep ‐Lorazepam – Avan Bromfed, Lodrane is too high or
    [Show full text]
  • Drug-Induced Movement Disorders
    Medical Management of Early PD Samer D. Tabbal, M.D. May 2016 Associate Professor of Neurology Director of The Parkinson Disease & Other Movement Disorders Program Mobile: +961 70 65 89 85 email: [email protected] Conflict of Interest Statement No drug company pays me any money Outline So, you diagnosed Parkinson disease .Natural history of the disease .When to start drug therapy? .Which drug to use first for symptomatic treatment? ● Levodopa vs dopamine agonist vs MAOI Natural History of Parkinson Disease Before levodopa: Death within 10 years After levodopa: . “Honeymoon” period (~ 5-7 years) . Motor (ON/OFF) fluctuations & dyskinesias: ● Drug therapy effective initially ● Surgical intervention by 10-15 years - Deep brain stimulation (DBS) therapy Motor Response Dyskinesia 5-7 yrs >10 yrs Dyskinesia ON state ON state OFF state OFF state time time Several days Several hours 1-2 hour Natural History of Parkinson Disease Prominent gait impairment and autonomic symptoms by 20-25 years (Merola 2011) Behavioral changes before or with motor symptoms: . Sleep disorders . Depression . Anxiety . Hallucinations, paranoid delusions Dementia at anytime during the illness . When prominent or early: diffuse Lewy body disease Symptoms of Parkinson Disease Motor Symptoms Sensory Symptoms Mental Symptoms: . Cognitive and psychiatric Autonomic Symptoms Presenting Symptoms of Parkinson Disease Mood disorders: depression and lack of motivation Sleep disorders: “acting out dreams” and nightmares Early motor symptoms: Typically Unilateral . Rest tremor: chin, arms or legs or “inner tremor” . Bradykinesia: focal and generalized slowness . Rigidity: “muscle stiffness or ache” Also: (usually no early postural instability) . Facial masking with hypophonia: “does not smile anymore” or “looks unhappy all the time” .
    [Show full text]
  • Treatment Options for Motor and Non-Motor Symptoms of Parkinson’S Disease
    biomolecules Review Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease Frank C. Church Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] Abstract: Parkinson’s disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopamin- ergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson’s (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine ago- nist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson’s disease.
    [Show full text]
  • Re-Submission Rasagiline 1Mg Tablet (Azilectò) (No
    Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (AzilectÒ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a resubmission rasagiline (AzilectÒ) is not recommended within NHS Scotland for the treatment of idiopathic Parkinson’s disease as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Rasagiline reduces off-time in patients with Parkinson’s disease and end of dose fluctuations on levodopa, similar to reductions shown with the less effective of two currently marketed catechol-O-methyl transferase inhibitors. The economic case has not been demonstrated. Overleaf is the detailed advice on this product. Chairman Scottish Medicines Consortium 1 Indication Treatment of idiopathic Parkinson’s disease as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Dosing information 1mg once daily Product availability date 4th July 2005 Summary of evidence on comparative efficacy Rasagiline is an irreversible inhibitor of the monoamine oxidase-B (MAO-B) enzyme. One effect of this enzyme inhibition is an increase in extracellular dopamine levels in the striatum, with subsequently increased dopaminergic activity. This is thought to be the mechanism of action of rasagiline in Parkinson’s disease (PD). Two double-blind trials recruited 687 and 472 adults, aged >30 years, with idiopathic PD defined by the presence of two cardinal signs (resting tremor, bradykinesia or rigidity) who experienced motor fluctuations for at least 1 hour per day (excluding morning akinesia) in the first study and for at least 2.5 hours per day in the second study, with a Hoehn and Yahr score <5 in the off-state.
    [Show full text]